MariTide
Investigational once-monthly injectable in Phase 3 development; three Phase 3 type 2 diabetes studies are planned to start in 2026.
What it is
Investigational once-monthly injectable for weight management and type 2 diabetes. It is in Phase 3 development and has no approval yet.
Why it matters to the stock. Obesity is the largest prospective market in Amgen's pipeline. Phase 3 timing and data determine whether MariTide can compete with leading obesity medicines.
News
No stories tagged to this project yet.